Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
    • Louder Than TB
  • Why New TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Pipeline
    • Discovery
    • Developing New Regimens
    • Engaging Communities
  • Access
    • Our Commitment
    • Understanding the TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • 20 Years of Impact
  • Donate

Search form

Latest News

February 1

ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets

January 28

New Report Reveals that R&D Partnerships Serving Neglected Communities have Produced Dozens of Life-Saving Innovations Since 2010

December 14

TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study

All News

Voices of TB

Videos from the Global Health Community

Kenya Launches Child-Friendly TB Medicine

New Childhood TB Medicines Will Help Save Lives

All Voices

Featured Publication

Accessing Improved TB Medicines for Children

  • Click here to download the full report

All Publications

Research Papers

No antimicrobial resistance research agenda without tuberculosis
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis
All Papers

For the Press

Press Contact:
Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

View the 2019 Annual Report
Join our mailing list and receive the latest news from TB Alliance.
Interests

Our Mission

TB Alliance is a not-for-profit organization dedicated to the discovery, development and delivery of better, faster-acting and affordable tuberculosis drugs that are available to those who need them.

Navigate

  • About
  • Why New TB Drugs?
  • R&D
  • Access
  • News
  • Donate

News Headlines

ZebiAI and TB Alliance Announce Collaboration to Apply ML-Driven Discovery Platform to Tuberculosis Targets
New Report Reveals that R&D Partnerships Serving Neglected Communities have Produced Dozens of Life-Saving Innovations Since 2010
TB Alliance Announces First Patient Dosed with TBAJ-587 in Phase 1 Study

Contact Us

Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings at the TB Alliance

Report a Concern

New York:

40 Wall Street, 24th floor, New York, NY 10005 • +1 212 227 7540

Pretoria:

Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328
© 2021 The TB Alliance. All Rights Reserved. Site by Darby Communications Report a Concern